tirzepatide origin Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review Tirzepatide (Mounjaro): 22.5% Weight Loss

Both Novo Nordisk and Lilly are responding to the competition to their obesity products from compounding pharmacies, which have been able to offer discounted versions of semaglutide and tirzepatide under FDA regulations applying to medicines deemed to be in short supply

Reusing needles or syringes introduces contamination from previous use

Metformin and risk of vitamin B12 deficiency: new advice

In the mid-2000s, Novo Nordisk had developed a peptide called liraglutide that mimics the gut hormone glucagon-like peptide-1 (GLP-1), leading to antidiabetic effects and weight loss

Glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., semaglutide in Ozempic and Wegovy) and the dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) work by mimicking naturally occurring hormones that regulate blood glucose and appetite

Individuals may experience tingling in their arms and legs, muscle twitches, prolonged anxiety and insomnia, and cognitive deficits as well as depression and mood swings that may be difficult to manage